Clinical Trials Logo

Multiple Myeloma, Relapsed clinical trials

View clinical trials related to Multiple Myeloma, Relapsed.

Filter by:
  • None
  • Page 1

NCT ID: NCT02043847 Completed - Clinical trials for Multiple Myeloma, Relapsed

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)

BMT-03
Start date: January 14, 2014
Phase: Phase 1
Study type: Interventional

In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will increase the dose of TMI until the maximum tolerated dose (MTD) is reached. Initial patients enrolled will receive the lowest possible dose of 3Gy. Maximum dose will be 9Gy.